Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
University Hospital Bonn · Goethe University Frankfurt · +23 more institutions
Indexed incrossrefdatacitepubmed
Abstract
No abstract available for this paper.
Citation impact
574
total citations
- FWCI
- 44.64
- Percentile
- 100%
- References
- 38
Citations per year
Authors
48Topics & keywords
Topics
Keywords
- Temozolomide
- Lomustine
- Medicine
- Glioblastoma
- Open label
- Oncology
- Internal medicine
- O-6-methylguanine-DNA methyltransferase
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.